We are a global company with a direct local presence in the UK. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities.
Up until May 2024, Hikma supplied its generic injectable medicines to UK hospitals through a third-party distributor. Since then, Hikma PLC's UK affiliate, Hikma Pharmaceuticals International Limited (Hikma UK), now assumes direct responsibility for selling these products to the NHS for hospital use.
Our products cover various therapeutic areas: anti-infectives, oncology, anaesthesia, central nervous system, cardiology, etc.
The marketing authorisations (MA) in the UK are owned by Hikma FarmacĂȘutica (Portugal) S.A, and our products are mainly manufactured in Europe, where Hikma has three manufacturing plants (Portugal, Germany and Italy).
We're committed to ensuring patients across the US, Canada, Europe, and the MENA region have access to high-quality medicines. Our priority is advancing health and wellbeing, which we achieve through empowering our people, protecting the environment and operating transparently and ethically.